Research on the effectiveness and safety of bronchial thermoplasty in patients with chronic obstructive pulmonary disease

Tao Wang, Peng Fu, Fa Long, Shengming Liu, Siyu Hu, Qiongping Wang, Zhihui Huang, Long Liang, Wenting Huang, Fengbo Hu, Jingfan Gan, Hongbo Dong, Guomei YanEuropean 2023 · DOI

Abstract

Combined bronchial thermoplasty (BT) therapy is superior to conventional medical treatment in improving lung function and quality of life of COPD patients. It also significantly reduces the COPD exacerbation risk without causing serious adverse events.

Introduction

Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of global mortality, characterized by irreversible airway obstruction and structural remodeling. While standard pharmacological treatments like bronchodilators and steroids manage symptoms, they often fail to address the underlying structural changes, such as smooth muscle hyperplasia. This randomized pilot study investigates Bronchial Thermoplasty (BT)—a radiofrequency ablation procedure typically reserved for severe asthma—as a potential interventional alternative for patients with moderate-to-severe COPD.

Study Design and Methodology

The researchers conducted a randomized pilot study involving 57 patients with moderate-to-severe COPD (GOLD grades II–IV). Participants were recruited from the Shenzhen Hospital of the Chinese Academy of Sciences and evaluated using High-Resolution Computed Tomography (HRCT) to assess emphysema severity.

Patients were randomized into two groups: a control group ($n=29$) receiving conventional inhalation therapy, and an intervention group ($n=28$) receiving conventional therapy plus BT. The BT procedure utilized a radiofrequency catheter to deliver controlled thermal energy to the airway walls across three separate sessions at intervals of at least three weeks.

Flowchart of the randomized pilot study, detailing patient recruitment, randomization, and follow-up procedures.

Clinical Outcomes and Lung Function

Primary outcomes were tracked at 3 and 12 months, focusing on spirometry, quality of life, and exercise capacity. The results at the 12-month mark demonstrated statistically significant improvements across nearly all metrics for the BT group.

Spirometry results showed that the BT group achieved significantly higher improvements in both Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) compared to the control group. Specifically, the improvement in FEV1 was highly significant ($P < 0.001$).

Comparison of mean Forced Vital Capacity (FVC) values between the control and intervention groups over a 12-month period.

Beyond lung function, exercise tolerance saw a dramatic increase. Patients in the BT group increased their 6-minute walk distance (6MWT) by an average of 78.07 meters, whereas the control group only improved by 31.52 meters.

Safety and Risk Reduction

One of the most critical findings was the reduction in exacerbation risk. The proportion of "high-risk" patients in the BT group plummeted from 100% at baseline to just 28.6% at one year. In contrast, 65.5% of the control group remained in the high-risk category. Furthermore, the cumulative number of hospitalizations in the BT group was significantly lower than both pre-treatment levels and the control group at follow-up ($P < 0.05$).

Safety evaluations indicated that no serious adverse events, such as death or permanent lung damage, occurred. Common side effects were limited to transient respiratory symptoms like cough and wheezing, which typically resolved within one week.

Mechanistic Insights

The study suggests that BT's efficacy in COPD may extend beyond simple muscle ablation. The authors hypothesize that the procedure may "denervate" parts of the lung, down-regulating overactive vagal nerve reflexes responsible for mucus hypersecretion. Additionally, BT may reduce the number of Pulmonary Neuroendocrine Cells (PNECs), which secrete chemicals like 5-HT that contribute to the inflammatory environment of the COPD lung.

Limitations and Future Work

While promising, the authors note several limitations, including the small sample size ($n=57$) and the lack of a sham-controlled surgical group to account for potential placebo effects in subjective scores. Future research should involve larger, multi-center trials and collect airway biopsies to confirm the hypothesized cellular and mechanistic changes. Additionally, investigating how different COPD phenotypes (e.g., chronic bronchitis vs. emphysema) respond to BT will be essential for refining patient selection.

Summary updated

Abstract

Combined BT therapy is superior to conventional medical treatment in improving lung function and quality of life of COPD patients, and it also significantly reduces the COPD exacerbation risk without causing serious adverse events.
BibTeX
@inproceedings{wang2023research,
  author = {Tao Wang and Peng Fu and Fa Long and Shengming Liu and Siyu Hu and Qiongping Wang and Zhihui Huang and Long Liang and Wenting Huang and Fengbo Hu and Jingfan Gan and Hongbo Dong and Guomei Yan},
  title = {{Research on the effectiveness and safety of bronchial thermoplasty in patients with chronic obstructive pulmonary disease}},
  booktitle = {European},
  year = {2023},
  doi = {10.1186/s40001-023-01319-9},
}
Figure